TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18924018

Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg daily for one week
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Esomeprazole
Number of subjects: 16
Study: 16424704

Group type: EXPERIMENTAL
Intervention: High-dose antithrombin III (30,000 IU intravenously over 4 days)
Number of subjects: 1008

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1008
Study: 12661672

Group type: EXPERIMENTAL
Intervention: Auditory modality verification (e.g., BLENDER-loud)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Same modality verification (e.g., LEAVES-rustling)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Different modality verification (e.g., CRANBERRIES-tart)
Number of subjects: 0
Study: 12670811

Group type: EXPERIMENTAL
Intervention: Sevoflurane plus fentanyl (Group B)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Isoflurane plus fentanyl (Group A)
Number of subjects: 20
Study: 10232637

Group type: EXPERIMENTAL
Intervention: Diet group (35% energy deficit; n = 22)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Diet + exercise group (35% net energy deficit; n = 22)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Control group (n = 23)
Number of subjects: 67
Study: 8724152

Group type: EXPERIMENTAL
Intervention: Single ablation zone (SA, 6.5 mm diameter)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Multipass multizone technique (MP, 3 zones)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: New software for three ablation zones in a single-pass (MZ)
Number of subjects: 75
Study: 1684604

Group type: EXPERIMENTAL
Intervention: Surgical hand disinfection with handwashing (soap without antimicrobial additives) and 5-min disinfection with 60% n-propanol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Surgical hand disinfection with 1-min disinfection (without prior handwashing)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Surgical hand disinfection with 5-min disinfection
Number of subjects: 0

Group type: COMPARATOR
Intervention: Retaining surgical gloves during interoperative break
Number of subjects: 0

Group type: COMPARATOR
Intervention: Removing surgical gloves during interoperative break
Number of subjects: 0
Study: 6575575

Group type: EXPERIMENTAL
Intervention: PGE2 tablets
Number of subjects: 387

Group type: COMPARATOR
Intervention: Demoxytocin resoriblets
Number of subjects: 387
Study: 30522577

Group type: EXPERIMENTAL
Intervention: PA program with a social adherence intervention (PASAI)
Number of subjects: 39

Group type: COMPARATOR
Intervention: PA program
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: PASAI program
Number of subjects: 39
Study: 29305709

Group type: EXPERIMENTAL
Intervention: Endurance training
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 12

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 12
Study: 26746876

Group type: EXPERIMENTAL
Intervention: Lunch is in the Bag intervention
Number of subjects: 633

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 633
Study: 24469936

Group type: EXPERIMENTAL
Intervention: Alcohol consumption during the follicular phase
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Alcohol consumption
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo consumption
Number of subjects: 24
Study: 23196556

Group type: EXPERIMENTAL
Intervention: High-frequency rTMS of primary motor cortex (M1) for neuropathic pain
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-frequency rTMS of affected M1 for 'Kaifukuki' rehabilitation
Number of subjects: 0
Study: 21305739

Group type: EXPERIMENTAL
Intervention: Molndal technique (Aquacel Ag‐Hydrofiber)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Traditional technique (gauze compresses and hypoallergic adhesives)
Number of subjects: 100
Study: 17225476

Group type: EXPERIMENTAL
Intervention: Zolpidem 20 mg (Zol-20)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Zolpidem 10 mg (Zol-10)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Melatonin 5 mg (Mel-5)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Melatonin 10 mg (Mel-10)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 15771635

Group type: EXPERIMENTAL
Intervention: Low-dose ERT (CEE 0.3125 mg/day) + SSRI (fluvoxamine 50 mg/day) for 8 weeks
Number of subjects: 42

Group type: COMPARATOR
Intervention: Low-dose ERT (CEE 0.3125 mg/day) for 8 weeks
Number of subjects: 42
Study: 12402196

Group type: EXPERIMENTAL
Intervention: Danaparoid (10 min after endotoxin)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Danaparoid (3 h after endotoxin)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 9690334

Group type: EXPERIMENTAL
Intervention: Quetiapine ('Seroquel')
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual-care antipsychotic medication
Number of subjects: 0
Study: 7640409

Group type: EXPERIMENTAL
Intervention: Proliferative phase
Number of subjects: 30

Group type: COMPARATOR
Intervention: Secretory phase
Number of subjects: 30
Study: 2655835

Group type: EXPERIMENTAL
Intervention: Duoderm dressing
Number of subjects: 8

Group type: COMPARATOR
Intervention: Omiderm dressing
Number of subjects: 8
Study: 201958

Group type: EXPERIMENTAL
Intervention: Equine conjugated oestrogens tablets (Premarin)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 29411999

Group type: EXPERIMENTAL
Intervention: Conventional curing practices (7 days undisturbed + 21 days curing)
Number of subjects: 5
Study: 28566028

Group type: EXPERIMENTAL
Intervention: Forensic Assertive Community Treatment (FACT)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Enhanced treatment as usual
Number of subjects: 70
Study: 26275649

Group type: EXPERIMENTAL
Intervention: Yoga training for 1 hour, 6 days a week for 12 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Brisk-walking with stretching exercise for 1 hour, 6 days a week for 12 weeks
Number of subjects: 60
Study: 23917775

Group type: EXPERIMENTAL
Intervention: Empty phosphatidylcholine liposomes (PCL)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Synthetic bacterial lipoprotein and TLR1/2 agonist Pam(3)CSK(4) (BLP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both PCL and BLP
Number of subjects: 0

Group type: COMPARATOR
Intervention: PCL
Number of subjects: 0
Study: 21912481

Group type: EXPERIMENTAL
Intervention: Mushroom extract
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Listerine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (water)
Number of subjects: 30
Study: 18312069

Group type: EXPERIMENTAL
Intervention: CD-ROM plus an educator-led didactic session
Number of subjects: 47

Group type: COMPARATOR
Intervention: Didactic session alone
Number of subjects: 47
Study: 16807414

Group type: EXPERIMENTAL
Intervention: Standard dose N-acetylcysteine (600 mg IV bolus before angioplasty and 600 mg orally twice daily for 48 hours after angioplasty)
Number of subjects: 354

Group type: EXPERIMENTAL
Intervention: High dose N-acetylcysteine (1200 mg IV bolus and 1200 mg orally twice daily for 48 hours after intervention)
Number of subjects: 354

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 354

Group type: EXPERIMENTAL
Intervention: Overall in-hospital mortality
Number of subjects: 354

Group type: EXPERIMENTAL
Intervention: Standard dose N-acetylcysteine
Number of subjects: 354

Group type: EXPERIMENTAL
Intervention: High dose N-acetylcysteine
Number of subjects: 354

Group type: EXPERIMENTAL
Intervention: Composite endpoint (death, acute renal failure requiring temporary renal-replacement therapy, or need for mechanical ventilation)
Number of subjects: 354
Study: 12681523

Group type: EXPERIMENTAL
Intervention: Low dose modafinil (200 mg/day)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: High dose modafinil (400 mg/day)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 11382829

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygenation (HBO) at 2 atm abs and 2.8 atm abs
Number of subjects: 15
Study: 9243352

Group type: EXPERIMENTAL
Intervention: Intravenous selegiline (0.5 mg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Oral selegiline (0.5 mg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Oral selegiline (1.0 mg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Oral selegiline (1.5 mg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Oral selegiline (5 mg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Oral selegiline (10 mg)
Number of subjects: 16
Study: 8491244

Group type: EXPERIMENTAL
Intervention: Dexamethasone 6 mg, administered orally once 12 hours before and once 12 hours after surgery
Number of subjects: 0
Study: 3438580

Group type: EXPERIMENTAL
Intervention: Abdominal muscle physiotherapy for 3 weeks
Number of subjects: 38

Group type: COMPARATOR
Intervention: Usual medical treatment
Number of subjects: 38
Study: 2116312

Group type: EXPERIMENTAL
Intervention: Meptazinol (loading dose 50 mg followed by i.v. infusion 0.5 mg.kg‐1.h‐1)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Morphine (loading dose 5 mg followed by i.v. infusion 0.05 mg.kg‐1.h‐1)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 30
Study: 30716679

Group type: EXPERIMENTAL
Intervention: Health promotion program based on self-efficacy theory
Number of subjects: 84

Group type: COMPARATOR
Intervention: Conventional health education
Number of subjects: 84
Study: 27686370

Group type: EXPERIMENTAL
Intervention: High ICFI scores (median score 6, IQR=4-7)
Number of subjects: 2092

Group type: EXPERIMENTAL
Intervention: Low DDS
Number of subjects: 2092
Study: 25475658

Group type: EXPERIMENTAL
Intervention: Low-glycemic-index and low-glycemic-load desserts (4 portions/week)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Usual sweet (1 portion/week)
Number of subjects: 61
Study: 24247559

Group type: EXPERIMENTAL
Intervention: Bevacizumab + capecitabine (maintenance therapy)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Bevacizumab + XELOX (induction therapy until progression)
Number of subjects: 123
Study: 20571769

Group type: EXPERIMENTAL
Intervention: Combined group (free hip protectors + education sessions)
Number of subjects: 479

Group type: EXPERIMENTAL
Intervention: No cost group (fitted with free hip protectors)
Number of subjects: 479

Group type: COMPARATOR
Intervention: Control group (brochure about hip protectors)
Number of subjects: 479
Study: 19583070

Group type: EXPERIMENTAL
Intervention: Intravenous dexmedetomidine (loading dose of 1 microg/kg over 10 min and maintenance dose of 0.5 microg/kg/hr)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Intravenous dexmedetomidine
Number of subjects: 48
Study: 17258823

Group type: EXPERIMENTAL
Intervention: 3-month lifestyle intervention
Number of subjects: 13

Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 13
Study: 12711925

Group type: COMPARATOR
Intervention: Alcohol consumption (exact dosage and duration not specified)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alcohol consumption
Number of subjects: 0
Study: 10229979

Group type: EXPERIMENTAL
Intervention: Traditional alkaline nasal douche
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Sterile sea water spray
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (standard treatment without douche)
Number of subjects: 40
Study: 8763802

Group type: EXPERIMENTAL
Intervention: HIV Overview of Problems Evaluation System (HOPES)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: EORTC Quality of Life Questionnaire (EORTC QLQ-C30)
Number of subjects: 106
Study: 1679517

Group type: EXPERIMENTAL
Intervention: beta-blockers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: beta1-selective blockers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: nonselective beta-blockers
Number of subjects: 0
Study: 7051761

Group type: COMPARATOR
Intervention: Sulfaisodimidine 1 g four times daily (Group I)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Sulfaisodimidine 2 g twice daily (Group II)
Number of subjects: 26
Study: 31962176

Group type: EXPERIMENTAL
Intervention: Supraglottic airway devices (SGA)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Impedance threshold device (ITD)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Endotracheal tube (ETT)
Number of subjects: 7
Study: 30455335

Group type: EXPERIMENTAL
Intervention: Intensive glucose control (HbA1c <7.0%)
Number of subjects: 1791

Group type: COMPARATOR
Intervention: Standard glucose control (HbA1c <8.5%)
Number of subjects: 1791

Group type: EXPERIMENTAL
Intervention: Severe hypoglycemia
Number of subjects: 1791

Group type: COMPARATOR
Intervention: Standard therapy after severe hypoglycemia
Number of subjects: 1791
Study: 26875447

Group type: COMPARATOR
Intervention: 20% protein diet
Number of subjects: 80

Group type: COMPARATOR
Intervention: 27% protein diet
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 35% protein diet
Number of subjects: 80
Study: 25470529

Group type: EXPERIMENTAL
Intervention: Transitional care programme (TCP), a nurse‐led 4‐week programme
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Transitional care programme (TCP)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 108
Study: 23312435

Group type: EXPERIMENTAL
Intervention: Maintenance cognitive therapy (MCT)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Therapeutic alliance and patient characteristics
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Homework compliance
Number of subjects: 54
Study: 21261433

Group type: EXPERIMENTAL
Intervention: Brief Strategic Family Therapy
Number of subjects: 480

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 480
Study: 19697822

Group type: EXPERIMENTAL
Intervention: 1 mg kg(‐1) rocuronium (group E)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: 0.1 mg kg(‐1) cis‐atracurium (group N)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: 1.5 mg kg(‐1) suxamethonium (group P)
Number of subjects: 70
Study: 17085458

Group type: EXPERIMENTAL
Intervention: Endurance training (14 weeks)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Continued endurance training (additional 14 weeks)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Detraining (14 weeks)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Endurance training
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Detraining
Number of subjects: 8
Study: 15209772

Group type: EXPERIMENTAL
Intervention: Insulin aspart
Number of subjects: 155

Group type: COMPARATOR
Intervention: Human insulin
Number of subjects: 155
Study: 11110932

Group type: EXPERIMENTAL
Intervention: Computed radiography
Number of subjects: 269

Group type: COMPARATOR
Intervention: Conventional screen-film radiography
Number of subjects: 269
Study: 9361690

Group type: EXPERIMENTAL
Intervention: Pirenzepine (PZP) 100 mg orally
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 1315100

Group type: EXPERIMENTAL
Intervention: Incision plus curettage and primary suture under antibiotic (Clindamycin) cover
Number of subjects: 32

Group type: COMPARATOR
Intervention: Conventional marsupialization
Number of subjects: 32
Study: 3883264

Group type: EXPERIMENTAL
Intervention: Metronidazole 400 mg administered one hour before and again four and eight hours after abortion
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Metronidazole prophylaxis
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Metronidazole
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo (ampicillin/pivampicillin)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Metronidazole and Placebo
Number of subjects: 100
Study: 30629845

Group type: EXPERIMENTAL
Intervention: Cow milk formula
Number of subjects: 0

Group type: COMPARATOR
Intervention: Extensively hydrolyzed protein formula
Number of subjects: 0
Study: 29106076

Group type: EXPERIMENTAL
Intervention: 4F‐PCC (50 IU kg‐1)
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: TXA (1.0 g)
Number of subjects: 147

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 147
Study: 27710596

Group type: EXPERIMENTAL
Intervention: Quercetin (500 mg/day)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 25144550

Group type: EXPERIMENTAL
Intervention: IS + EPAP
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control
Number of subjects: 14
Study: 23321990

Group type: EXPERIMENTAL
Intervention: Abstinence plus condom use
Number of subjects: 300

Group type: COMPARATOR
Intervention: Abstinence only
Number of subjects: 300
Study: 21205050

Group type: EXPERIMENTAL
Intervention: Brief intervention
Number of subjects: 616

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 616
Study: 18537053

Group type: EXPERIMENTAL
Intervention: L-arginine
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Resting mean flow velocity
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Pulsatility index (PI)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: L-arginine application
Number of subjects: 49
Study: 17143986

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral treatment plus usual care
Number of subjects: 409

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 409
Study: 12655281

Group type: EXPERIMENTAL
Intervention: Trimetazidine (TMZ)
Number of subjects: 12
Study: 10929922

Group type: EXPERIMENTAL
Intervention: Loratadine 10 mg once daily
Number of subjects: 659

Group type: COMPARATOR
Intervention: Fexofenadine 60 mg twice daily
Number of subjects: 659

Group type: EXPERIMENTAL
Intervention: Switching to loratadine after initial therapy with fexofenadine
Number of subjects: 659

Group type: COMPARATOR
Intervention: Switching to fexofenadine after initial therapy with loratadine
Number of subjects: 659
Study: 9052131

Group type: EXPERIMENTAL
Intervention: Developmentally appropriate instructional program on germs and handwashing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual handwashing procedures (Control)
Number of subjects: 0
Study: 8094826

Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal coronary angioplasty (PTCA)
Number of subjects: 1011

Group type: COMPARATOR
Intervention: Coronary artery bypass surgery (CABG)
Number of subjects: 1011

Group type: EXPERIMENTAL
Intervention: PTCA
Number of subjects: 1011

Group type: COMPARATOR
Intervention: CABG
Number of subjects: 1011
Study: 3535757

Group type: EXPERIMENTAL
Intervention: Fenofibrate (100 mg three times daily)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study: 29940952

Group type: EXPERIMENTAL
Intervention: Panel of circulating microRNAs combined with exacerbation clinical score
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: 12 well-detected circulating microRNAs
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: 3-microRNA model (miR-146b, miR-206, miR-720)
Number of subjects: 153
Study: 27184170

Group type: EXPERIMENTAL
Intervention: Alirocumab 50 mg
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Alirocumab 75 mg
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Alirocumab 150 mg
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 25068344

Group type: EXPERIMENTAL
Intervention: Autologous fat injection (group A)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Autologous fat injection with plasma rich in growth factors (group B)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 49
Study: 22926606

Group type: EXPERIMENTAL
Intervention: risperidone
Number of subjects: 289

Group type: COMPARATOR
Intervention: haloperidol
Number of subjects: 289
Study: 20621285

Group type: EXPERIMENTAL
Intervention: Implied auditory elements in sentences
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control task (unrelated sound categorization task)
Number of subjects: 0
Study: 18971381

Group type: EXPERIMENTAL
Intervention: Body weight supported treadmill training (BWSTT)
Number of subjects: 13
Study: 17041232

Group type: EXPERIMENTAL
Intervention: Computer-assisted decision support technology
Number of subjects: 1286

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 1286
Study: 12975743

Group type: EXPERIMENTAL
Intervention: Endovascular coiling
Number of subjects: 100

Group type: COMPARATOR
Intervention: Surgical clipping
Number of subjects: 100
Study: 10634841

Group type: EXPERIMENTAL
Intervention: 4% amethocaine gel (Ametop)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 60
Study: 8124992

Group type: EXPERIMENTAL
Intervention: Band electrodes
Number of subjects: 21

Group type: COMPARATOR
Intervention: Spot electrodes
Number of subjects: 21
Study: 2671112

Group type: EXPERIMENTAL
Intervention: SMS 201‐995 (50 micrograms)
Number of subjects: 8
Study: 793304

Group type: EXPERIMENTAL
Intervention: Baclofen
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 31290018

Group type: EXPERIMENTAL
Intervention: Direct Technique (DT)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Semidirect Technique (SDT)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Both techniques (DT and SDT)
Number of subjects: 30
Study: 30414260

Group type: EXPERIMENTAL
Intervention: Insulin glargine 300 U/mL (Gla‐300)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Insulin glargine 100 U/mL (Gla‐100)
Number of subjects: 0
Study: 27979383

Group type: EXPERIMENTAL
Intervention: Atezolizumab 1200 mg every 3 weeks
Number of subjects: 1225

Group type: COMPARATOR
Intervention: Docetaxel 75 mg/m2 every 3 weeks
Number of subjects: 1225

Group type: EXPERIMENTAL
Intervention: Atezolizumab in PD-L1 expression population (TC1/2/3 or IC1/2/3)
Number of subjects: 1225

Group type: COMPARATOR
Intervention: Docetaxel in PD-L1 expression population (TC1/2/3 or IC1/2/3)
Number of subjects: 1225

Group type: EXPERIMENTAL
Intervention: Atezolizumab in PD-L1 low or undetectable subgroup (TC0 and IC0)
Number of subjects: 1225

Group type: COMPARATOR
Intervention: Docetaxel in PD-L1 low or undetectable subgroup (TC0 and IC0)
Number of subjects: 1225

Group type: EXPERIMENTAL
Intervention: Atezolizumab
Number of subjects: 1225

Group type: COMPARATOR
Intervention: Docetaxel
Number of subjects: 1225
Study: 26369410

Group type: EXPERIMENTAL
Intervention: Performance-based financing (PBF)
Number of subjects: 5781

Group type: COMPARATOR
Intervention: Comparison group (no PBF)
Number of subjects: 5781
Study: 22491891

Group type: EXPERIMENTAL
Intervention: Denicotinized cigarettes
Number of subjects: 22

Group type: COMPARATOR
Intervention: Average nicotine cigarettes
Number of subjects: 22